BioVie Inc
BIVI
Company Profile
Business description
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Contact
680 W Nye Lane
Suite 204
CarsonNV89703
USAT: +1 775 888-3162
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
14
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,688.00 | 35.50 | -0.41% |
| CAC 40 | 7,565.57 | 24.09 | -0.32% |
| DAX 40 | 23,320.01 | 30.54 | -0.13% |
| Dow JONES (US) | 42,206.82 | 35.16 | 0.08% |
| FTSE 100 | 8,762.40 | 12.25 | -0.14% |
| HKSE | 23,659.74 | 129.26 | 0.55% |
| NASDAQ | 19,447.41 | 98.86 | -0.51% |
| Nikkei 225 | 38,354.09 | 49.14 | -0.13% |
| NZX 50 Index | 12,532.65 | 36.40 | -0.29% |
| S&P 500 | 5,967.84 | 13.03 | -0.22% |
| S&P/ASX 200 | 8,474.90 | 30.60 | -0.36% |
| SSE Composite Index | 3,381.58 | 21.69 | 0.65% |